Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series
Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series
About this item
Full title
Author / Creator
Cadranel, Jacques , Liu, Stephen V. , Duruisseaux, Michaël , Branden, Eva , Goto, Yasushi , Weinberg, Benjamin A. , Heining, Christoph , Schlenk, Richard F. , Cheema, Parneet , Jones, Martin R. , Drilon, Alexander , Trombetta, Domenico , Muscarella, Lucia Anna , Tolba, Khaled , Gounant, Valerie , Cseh, Agnieszka , Solca, Flavio , Laskin, Janessa J. and Renouf, Daniel J.
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Hoboken, USA: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Neuregulin 1 (NRG1) fusions, which activate ErbB signaling, are rare oncogenic drivers in multiple tumor types. Afatinib is a pan‐ErbB family inhibitor that may be an effective treatment for NRG1 fusion‐driven tumors.
Patients and Methods
This report summarizes pertinent details, including best tumor response to treatment, for s...
Alternative Titles
Full title
Therapeutic Potential of Afatinib in NRG1 Fusion‐Driven Solid Tumors: A Case Series
Authors, Artists and Contributors
Author / Creator
Liu, Stephen V.
Duruisseaux, Michaël
Branden, Eva
Goto, Yasushi
Weinberg, Benjamin A.
Heining, Christoph
Schlenk, Richard F.
Cheema, Parneet
Jones, Martin R.
Drilon, Alexander
Trombetta, Domenico
Muscarella, Lucia Anna
Tolba, Khaled
Gounant, Valerie
Cseh, Agnieszka
Solca, Flavio
Laskin, Janessa J.
Renouf, Daniel J.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7794194
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7794194
Other Identifiers
ISSN
1083-7159
E-ISSN
1549-490X
DOI
10.1634/theoncologist.2020-0379
